drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Chimeric type I IgG1 monoclonal antibody targeting CD20 on B cells; depletes CD20+ pre-B and mature B cells via ADCC, CDC, and apoptosis to reduce autoantibody production and inflammatory signaling. Includes MabThera brand and biosimilar comparator.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric type I IgG1 monoclonal antibody against CD20 on pre‑B and mature B cells; binds CD20 and depletes CD20+ B cells via antibody‑dependent cellular cytotoxicity (ADCC), complement‑dependent cytotoxicity (CDC), and induction of apoptosis, thereby reducing autoantibody production and inflammatory signaling.
drug_name
Rituximab
nct_id_drug_ref
NCT06175338